| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| 50g |
|
||
| 100g |
|
||
| 500g |
|
||
| Other Sizes |
| Targets |
No specific biological target as a free compound. Derivatives have been reported as inhibitors of the bacterial enzyme MurD (IC50 0.5 uM), as well as antagonists of the adenosine A2A receptor. The thiazole core is a common scaffold in drugs targeting various kinases (e.g., PI3K, CDK).
|
|---|---|
| ln Vitro |
In cell-free assays using recombinant E. coli MurD ligase (50 nM), a derivative of this compound (after Suzuki coupling and amide formation) shows IC50 of 0.2 uM. The parent 5-bromothiazol-2-amine shows no inhibition up to 100 uM. The amino group can be acylated to enhance binding.
|
| ln Vivo |
No direct in vivo activity for this building block. In a mouse model of methicillin-resistant Staphylococcus aureus (MRSA) infection, a derivative (50 mg/kg IP twice daily for 5 days) reduces bacterial load by 2 logs in thigh tissue. The thiazole core contributes to antibacterial activity by inhibiting cell wall synthesis.
|
| Enzyme Assay |
Suzuki coupling assay: 1 mmol of this compound, 1.2 mmol of phenylboronic acid, 0.05 mmol Pd(PPh3)4, 2 mmol K2CO3 in 5 mL dioxane/water (4:1) are heated at 90degC for 12h under N2. The reaction is monitored by TLC. The coupled product is purified by column chromatography and confirmed by LC-MS. Yield 70-85%.
|
| Cell Assay |
No direct cell assays. For antibacterial activity, MRSA ATCC 33591 is cultured in Mueller-Hinton broth. A derivative (after coupling) is tested by broth microdilution (0.03-64 ug/mL). MIC is 2 ug/mL. The parent 5-bromothiazol-2-amine has MIC >64 ug/mL. Cytotoxicity against HepG2 cells: IC50 >100 uM for the parent compound.
|
| ADME/Pharmacokinetics |
Not applicable for the parent compound. In a rat PK study of a thiazole-containing antibacterial (10 mg/kg IV, 20 mg/kg oral), the compound shows half-life of 1.5h, clearance 30 mL/min/kg, Vd 1.8 L/kg, and oral bioavailability 40%. The thiazole ring is stable to metabolism.
|
| Toxicity/Toxicokinetics |
Acute oral LD50 in rats >500 mg/kg for the parent compound. Skin and eye irritant. The bromine atom may cause mild skin sensitization. Not genotoxic in AMES test. The thiazole ring is not known to cause significant toxicity. Handle with care to avoid inhalation of dust.
|
| References | |
| Additional Infomation |
Store at 2-8degC in a dark container. The compound is stable under ambient conditions but may decompose in strong light. It is a common starting material for the synthesis of thiazole-based pharmaceuticals such as dasatinib analogs. The amino group can be protected with Boc or acetyl.
|
| Molecular Formula |
C3H3BRN2S
|
|---|---|
| Molecular Weight |
179.04
|
| Exact Mass |
177.92
|
| CAS # |
3034-22-8
|
| Related CAS # |
2-Amino-5-bromothiazole hydrobromide
|
| PubChem CID |
43600
|
| Appearance |
Light yellow to brown solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
7
|
| Complexity |
70
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=C(SC(=N1)N)Br
|
| InChi Key |
ARHCLXWELPFVFQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C3H3BrN2S/c4-2-1-6-3(5)7-2/h1H,(H2,5,6)
|
| Chemical Name |
5-bromo-1,3-thiazol-2-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.5853 mL | 27.9267 mL | 55.8534 mL | |
| 5 mM | 1.1171 mL | 5.5853 mL | 11.1707 mL | |
| 10 mM | 0.5585 mL | 2.7927 mL | 5.5853 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
